New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss ...

Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 ...

Dr. Bhardwaj's pioneering approach has earned him widespread recognition, including the prestigious title of "World's Fastest ...

Novo Nordisk's obesity drug CagriSema failed to outperform Eli Lilly's Mounjaro in the latest trial, causing a dip in Novo's ...

It seems like no matter what I do, I can't lose weight. Most of my family members struggle with their weight too. Do our ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...

Novo Nordisk's experimental drug, CagriSema, demonstrated a 15.7% weight reduction in obese individuals with type 2 diabetes over 68 weeks. Key findings from the phase III REDEFINE 2 trial highlight ...

Most HHS workers were emailed an offer to leave their job for as much as $25,000 as part of President Trump’s government cuts ...

A new study breaks down exactly how to stop eating ultra-processed foods in eight weeks. Here's what it found and what ...

Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating ...